Research progress of sorafenib in tumor therapy

Abstract

Multi-kinase inhibitor Sola Fini (sorafenib), as the first approved multi-target agent, is a noval multi-target signal transduction inhibitors, which can inhibit the proliferation of tumor cells, prevent tumor angiogenesis and induce apoptosis of tumor cells. Studies have shown that Sola Fini imposes extensive antitumor activity on animal model of human tumor xenograft, such as mouse renal cell carcinoma, colon cancer, pancreatic cancer, thyroid cancer, non-small cell lung cancer, breast cancer and ovarian cancer model. In this paper, the mechanism of anti-tumor of sorafenib and the progress of tumor therapy are reviewed.